ME-401
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Conditions
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Trial Timeline
Apr 29, 2019 → Jan 15, 2025
NCT ID
NCT03985189About ME-401
ME-401 is a phase 1 stage product being developed by Kyowa Kirin for Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03985189. Target conditions include Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04533581 | Phase 2 | Active |
| NCT03985189 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma